CagriSema vs Liraglutide
A side-by-side research comparison of CagriSema and Liraglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Liraglutide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Liraglutide (GLP-1 Receptor Agonist / Saxenda) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Binds and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through hypothalamic signaling. |
| Molecular weight | Combination product | 3,751 Da |
| Half-life | 7 days (both components) | 13 hours |
| Bioavailability | High (SubQ) | ~55% (subcutaneous) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 0.6-3.0 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous | Subcutaneous |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Liraglutide reported benefits
- Proven weight loss (5-10%)
- Long safety track record
- Cardiovascular benefit
- Improved glycemic control
- Reduced food intake
Related comparisons
Research and educational reference only. Not medical advice.